Enliven Therapeutics (NASDAQ:ELVN) Hits New 52-Week High – Here’s What Happened

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $29.47 and last traded at $29.45, with a volume of 201485 shares traded. The stock had previously closed at $28.02.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Price Performance

The firm has a market cap of $1.38 billion, a PE ratio of -15.53 and a beta of 1.10. The business’s 50 day moving average price is $23.92 and its 200 day moving average price is $22.57.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.17. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,270 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total value of $35,140.90. Following the completion of the sale, the director now directly owns 124,490 shares in the company, valued at $3,444,638.30. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CFO Benjamin Hohl sold 991 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $27.53, for a total value of $27,282.23. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Richard A. Heyman sold 1,270 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $27.67, for a total value of $35,140.90. Following the sale, the director now directly owns 124,490 shares of the company’s stock, valued at approximately $3,444,638.30. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 180,409 shares of company stock valued at $4,800,526. Corporate insiders own 29.20% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the business. Quest Partners LLC boosted its position in shares of Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the period. American Century Companies Inc. boosted its position in shares of Enliven Therapeutics by 44.7% during the second quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after buying an additional 8,540 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics in the first quarter valued at $167,000. SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics in the 3rd quarter valued at $256,000. Finally, Rhumbline Advisers raised its holdings in shares of Enliven Therapeutics by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after buying an additional 11,420 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.